Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06770582 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 160 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Study sites: 145 to 147
  2. Site details revised at 2 of 145 sites
  3. Trial sites expanded: 142 → 145 locations Site details revised at 2 of 145 sites Show 1 more changeShow less
    • Site details revised at 2 of 145 sites
  4. Study sites: 142 to 145
  5. Study sites: 140 to 142
Show 19 earlier versionsHide 19 earlier versions
  1. Study sites: 138 to 140
  2. Study sites: 136 to 138v154
  3. Site contacts updated at 3 of 136 sitesv153
  4. Study sites: 135 to 136v152
  5. Study sites: 133 to 135v151
  6. Study sites: 134 to 133v150
  7. Study sites revised (134)v149 See this version in full on ClinicalTrials.gov ↗
  8. Site details revised at 2 of 134 sitesv148
  9. Site details revised at 1 of 134 sitesv147
  10. Site details revised at 1 of 134 sitesv146
  11. Site details revised at 1 of 134 sitesv145
  12. Site details revised at 1 of 134 sitesv144
  13. Study sites: 133 to 134v143
  14. Study sites: 132 to 133v142
  15. Study sites: 130 to 132v141
  16. Study sites: 129 to 130v140
  17. Site contacts updated at 1 of 129 sitesv139
  18. Study sites: 128 to 129v138
  19. Site details revised at 2 of 128 sitesv137
  1. Trial sites expanded: 125 → 128 locationsv136
  2. Site details revised at 8 of 125 sitesv135
  3. Site details revised at 3 of 125 sitesv134
  4. Study sites: 124 to 125v133
  5. Study sites: 123 to 124v132
  6. Study sites: 122 to 123v131
  7. Study sites: 121 to 122v130
  8. Re-verified, no change to tracked fieldsv129
  9. Study sites: 120 to 121v128
  10. 5 versions Re-verified since Apr 1, 2026, no change to tracked fieldsv123-v127
  11. Trial sites expanded: 114 → 120 locations Site details revised at 1 of 120 sitesv122 Show 1 more changeShow less
    • Site details revised at 1 of 120 sites
  12. Study sites: 114 to 120v121
  13. Study sites: 113 to 114v120
  14. 8 versions Re-verified since Mar 17, 2026, no change to tracked fieldsv112-v119
  15. Study sites: 109 to 113v111
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II trial compares the use of pembrolizumab and radiation therapy to chemotherapy with cisplatin, gemcitabine, 5-fluorouracil or mitomycin-C and radiation therapy for the treatment of non-muscle invasive bladder cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, gemcitabine, 5-fluorouracil or mitomycin-C, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Giving pembrolizumab with radiation may kill more tumor cells than chemotherapy with radiation therapy in patients with non-muscle invasive bladder cancer.
Trial Details
NCT Number NCT06770582
Lead Sponsor National Cancer Institute (NCI)
Conditions Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage I Bladder Cancer AJCC v8
Enrollment 160 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov